Division of Cardiothoracic Surgery, Department of Surgery, Emory University School of Medicine, Atlanta, Georgia 30322, USA.
Ann Thorac Surg. 2011 Mar;91(3):823-9; discussion 829-30. doi: 10.1016/j.athoracsur.2010.11.031.
Previous studies have reported that children with a prior Fontan procedure have decreased survival after heart transplantation. We examined 190 primary pediatric heart transplants.
Since 1988, 27 (14.2%) of 190 children less than 18 years old undergoing primary heart transplantation had a Fontan procedure 3.7 ± 4.3 years before transplantation. Compared with 163 (85.8%) non-Fontan primary transplants, the Fontan patients were similar in age (8.2 ± 5.0 vs 6.5 ± 6.0 years), presensitization, and pretransplant clinical status. More Fontan patients had prior operations (100% vs 50%; p < 0.0001) and needed pulmonary artery reconstruction (100% vs 23.5%; p < 0.0001). Twelve (44%) had protein-losing enteropathy.
Donor ischemic times (211 ± 72 vs 170 ± 61 minutes; p = 0.0018) and cardiopulmonary bypass times (197 ± 91 vs 121 ± 53 minutes; p < 0.0001) were greater in the Fontan group as were durations of ventilator support (4.9 ± 6.6 vs 2.6 ± 3.9 days; p = 0.018) and hospital stay (20.2 ± 17.5 vs 14.3 ± 12.4 days; p = 0.0435). The Fontan group had one 30-day mortality. One-year actuarial survival (81.5% vs 84.6%, Fontan vs non-Fontan) and five-year actuarial survival (65.5% vs 66.2%, Fontan vs non-Fontan) were similar, as was rejection incidence at one year (2.0 ± 2.0 vs 1.7 ± 1.9 episodes per patient; p = 0.3972). Five Fontan patients (18.5%) required retransplantation 4.9 ± 3.6 years posttransplant compared with 18 non-Fontan patients (11.0%) retransplanted 5.2 ± 3.4 years posttransplant (p = 0.3346).
Contrary to prior reports, we did not identify any early or midterm disadvantage for children undergoing heart transplantation after a previous Fontan procedure despite more complex transplant operations. We contend that carefully selected children with a failing Fontan circulation can do as well as other children with heart transplantation.
先前的研究报告表明,先前接受过 Fontan 手术的儿童在心脏移植后存活率降低。我们检查了 190 例原发性儿科心脏移植患者。
自 1988 年以来,190 例年龄小于 18 岁的儿童中,有 27 例(14.2%)在移植前 3.7±4.3 年前接受过 Fontan 手术。与 163 例(85.8%)非 Fontan 原发性移植相比,Fontan 患者在年龄(8.2±5.0 岁 vs 6.5±6.0 岁)、致敏和移植前临床状况方面相似。更多的 Fontan 患者接受过先前的手术(100% vs 50%;p<0.0001)和肺动脉重建(100% vs 23.5%;p<0.0001)。12 例(44%)有蛋白丢失性肠病。
Fontan 组的供体缺血时间(211±72 分钟 vs 170±61 分钟;p=0.0018)和体外循环时间(197±91 分钟 vs 121±53 分钟;p<0.0001)较长,呼吸机支持时间(4.9±6.6 天 vs 2.6±3.9 天;p=0.018)和住院时间(20.2±17.5 天 vs 14.3±12.4 天;p=0.0435)也较长。Fontan 组有 1 例 30 天死亡率。1 年的实际生存率(81.5% vs 84.6%,Fontan vs 非 Fontan)和 5 年的实际生存率(65.5% vs 66.2%,Fontan vs 非 Fontan)相似,1 年的排斥发生率(2.0±2.0 次/患者 vs 1.7±1.9 次/患者;p=0.3972)也相似。5 例(18.5%)Fontan 患者在移植后 4.9±3.6 年需要再次移植,而 18 例(11.0%)非 Fontan 患者在移植后 5.2±3.4 年需要再次移植(p=0.3346)。
与先前的报告相反,尽管 Fontan 手术后的心脏移植手术更为复杂,但我们没有发现任何早期或中期对儿童的不利影响。我们认为,经过精心选择的 Fontan 循环衰竭儿童与其他接受心脏移植的儿童一样可以做得很好。